Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Under enrollment and IP supply expiring.

Conditions

Healthy
Asthma

Interventions

DRUG: JNJ-43260295
DRUG: Placebo
DRUG: Nasal Allergen Challenge

Sponsor

Janssen Research & Development, LLC